Study uncovers mutation impacting Alzheimer's progression

NewsGuard 100/100 Score

The scientist of the Faculty of Medicine of the University of Malaga José Luis Royo has coordinated a study that summarizes eight years of research and brings together 100 multidisciplinary specialists, identifying a mutation that alters Alzheimer's disease progression.

This work, published in 'Journal of Alzheimer's Disease', has characterized a genetic variant in SIRPβ1 gene, which affects the way in which the immune system fights against beta-amyloid deposits, the cause that leads to this pathology.

In conducting this work, a longitudinal study was carried out using epidemiological samples of more than 1,300 patients from Malaga and Barcelona, evidencing the role of this mutation in the cognitive decline of those affected. However, it was found that it does not represent a risk factor in itself for Alzheimer's disease.

All human beings have the same genes, but there are variants of each one that make us different. Different external appearances and, also, different physiologies and metabolisms."

José Luis Royo, Professor of the Department of Surgical Specialties, Biochemistry and Immunology

The UMA scientist points out that an analysis of the presence of this variant in the SIRPβ1 gene showed that 30 percent of the general population has one mutation copy and 4 percent of the population has both copies affected. "Therefore, we are talking about a variant that is very present in the general population," he says.

Dual effect

The research, which involves scientists from more than 50 different entities, shows that the mutant variant changes the structure of the protein and how this alters the behavior of brain immune cells, called microglia.

"When we studied its role in the course of the disease, we found out that it has a dual effect depending on the disease stage: at the beginning, in patients with mild cognitive impairment, the mutation increases the conversion risk to Alzheimer's disease, so it has a detrimental effect in early stages; however, when dementia is established as such, those mutation carriers show slower cognitive decline, suggesting a beneficial effect among these patients", clarifies the UMA researcher.

Royo points out that, therefore, the mutation affects the immune system response to beta-amyloid deposits, probably to the neuroinflammation process, which is a physiological response in the early stages but harmful if it becomes chronic as the disease progresses.

Thus, this dual effect of the genetic variant, he says, suggests that this cell signaling pathway should be inhibited during the early stages of the disease, but it should be stimulated in patients in more advanced stages, to chemically mimic the effect generated by the mutation. "This finding opens the door to a new biochemical therapeutic target that, in the future, could be synthesized with a drug", he concludes.

Currently, researchers keep working to characterize the effect of this mutation at a higher level of complexity and have designed a system to look for modifiers of this cell signaling pathway.

Multidisciplinary scientific team

'An Insertion Within SIRPβ1 Shows a Dual Effect Over Alzheimer's Disease Cognitive Decline Altering the Microglial Response' is a multidisciplinary work in which 100 researchers from more than 50 different entities have participated, including the Andalusian Institute of Neuroscience (IANEC) of Malaga, the Faculty of Science of the UMA, the ACE Foundation and the Centre for Genomic Regulation (CRG) in Barcelona, the Institute of Biomedicine of Seville (IBIS) and the Andalusian Center for Developmental Biology (CABD), among many others.

Journal reference:

García-Alberca, J. M., et al. (2024). An Insertion Within SIRPβ1 Shows a Dual Effect Over Alzheimer’s Disease Cognitive Decline Altering the Microglial Response. Journal of Alzheimer’s Disease.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Dietary vitamin A shows promise in Alzheimer's disease intervention, study finds